Balversa (erdafitinib) — CareFirst (Caremark)
Urothelial carcinoma – Primary carcinoma of the urethra
Initial criteria
- Diagnosis of primary carcinoma of the urethra with FGFR3 genetic alterations
- Used as a single agent
- Used as subsequent therapy for locally advanced, recurrent, or metastatic disease
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months